Researchers to Report New Results Generated on Ion Torrent PGM Sequencer at AGBT
Rapid Pace of Development of
The vendor community is also embracing Ion semiconductor sequencing
technology because the system's simplicity and affordability is opening
the sequencing market to tens of thousands of researchers and
clinicians. Companies including Diagenode, CLC bio,
"When you democratize something, you can build a community, and that's
what we're rapidly seeing develop around Ion Torrent, on both the user
and the vendor side," said Dr.
Ion semiconductor sequencing, which is at the heart of the Ion Personal Genome Machine (PGM™) sequencer has already demonstrated a consistent 10x improvement in throughput every six months during the system's development, and continued increases along that trajectory promise to radically transform DNA sequencing for all scientists.
Data generated on the Ion Torrent PGM sequencer and presented at AGBT
will focus on the sequencing of amplicons, microbial genomes and
barcoded samples. The researchers presenting at AGBT on
Long Le, research collaborator of Dr. John Iafrate, Director of the Diagnostic Molecular Pathology Laboratory, early Ion Torrent adopters from Massachusetts General Hospital
Chad Nusbaumfrom the Broad Institute
Stephan Schusterfrom Pennsylvania State University
Donna Muznyfrom Baylor College of Medicine
Joe Bolandfrom SAIC-Frederick
Applications developed by the Ion Torrent community are focusing both on solutions that lie upstream and downstream of DNA sequencing.
Upstream Solutions from the
"The potential speed and simplicity of the system we hope will allow us to analyze multiple samples in an efficient manner," said Dr. Iafrate. "These features would be essential for incorporating high-throughput sequencing technologies into clinical applications."
For researchers interested in sequencing whole genomes,
Downstream Solutions from the
Ion Torrent is also partnering with CLC bio, Partek and DNASTAR, three companies that have a long history of delivering world-class bioinformatics solutions and services.
"I generate and analyze my own data and by using bioinformatics tools
from companies like DNASTAR and Partek, I'm able to significantly
decrease my time to results and focus on the next experiment rather than
struggling through data analysis," said Dr.
Data management can also be a significant hurdle for many scientists, so
In addition to partnering with leading vendors,
About the Life Grand Challenges Contest
Grand Challenges Contest is a first-of-its-kind crowd sourcing
initiative focused on the life sciences tools and technology industry.
The goal of the
There will be seven individual challenges, each with a
The three Ion challenges are to 1) produce twice as much sequence data, 2) do it twice as fast, and 3) do it with twice the accuracy. The SOLiD challenge is to sequence both the genome and the RNA content of a single cancer cell, effectively doubling the biological readout that is currently achievable by sequencing a single cell.
To receive the most up-to-date information on the various challenges, please register at www.lifetechnologies.com/grandchallenges, and please join the conversation on Twitter: @Grand_Challenge.
About Life Technologies Next-Generation Sequencing
The 5500 Series SOLiD and Ion Torrent Sequencers are for research use only, and are not intended for animal or human therapeutic or diagnostic use.
Research Use Only
The Ion PGM Sequencer is for research use only, and not intended for animal or human therapeutic or diagnostic use.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties.
Some of the information contained in this press release, including, but
not limited to, statements as to industry trends and Life Technologies'
plans, objectives, expectations and strategy for its business, contains
forward-looking statements that are subject to risks and uncertainties
that could cause actual results or events to differ materially from
those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan,"
"intend," "anticipate," "target," "estimate," "expect" and the like,
and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of
these forward-looking statements. Important factors which could cause
actual results to differ materially from those in the forward-looking
statements are detailed in filings made by Life Technologies with the
News Provided by Acquire Media